CAMBRIDGE, MA, Stylus Medicine, a biotechnology company dedicated to developing transformative in vivo genetic medicines, today emerges from stealth with $85 million in financing.
Stylus' funding includes a $45 million Series A extension financing with participation from RA Capital Management, Khosla Ventures, and six new investors including Chugai Venture Fund, Eli Lilly and Company, and Johnson & Johnson Innovation - JJDC. This financing follows a $40 million Series A investment from founding investors RA Capital and Khosla Ventures.
Stylus Medicine is developing transformative in vivo genetic medicines to unlock cures. Stylus combines engineered recombinases with non-viral delivery to specifically encode therapeutics. The company's approach is versatile and modular, with potential therapeutic application across oncology, autoimmune, genetic diseases, and beyond.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
